Obtaining efficient drug delivery to the brain remains the biggest challenge for the development of therapeutics to treat diseases of the central nervous system. The main …
KE Sapsford, WR Algar, L Berti, KB Gemmill… - Chemical …, 2013 - ACS Publications
Bionanotechnology has now become firmly established in its own right as one of the principle and focused subdisciplines within nanotechnology.(1-10) Bionanotechnology can …
M Masserini - International Scholarly Research Notices, 2013 - Wiley Online Library
The central nervous system, one of the most delicate microenvironments of the body, is protected by the blood‐brain barrier (BBB) regulating its homeostasis. BBB is a highly …
Alzheimer's disease (AD) is a progressive deterioration of brain function, initially characterized by cognitive deficits, with loss of recent memory and language ability …
A variety of neuroprotectants have shown promise in treating ischemic stroke, yet their delivery to the brain remains a challenge. The endothelial cells lining the blood-brain barrier …
S Martins, B Sarmento, DC Ferreira… - International journal of …, 2007 - Taylor & Francis
This paper highlights the importance of lipid-based colloidal carriers and their pharmaceutical implications in the delivery of peptides and proteins for oral and parenteral …
KY Lee, SH Yuk - Progress in polymer science, 2007 - Elsevier
Although various peptide and protein drugs have been developed for therapeutic purposes, several challenges can still be encountered, including a relatively short half-life within the …
AG De Boer, PJ Gaillard - Annu. Rev. Pharmacol. Toxicol., 2007 - annualreviews.org
The central nervous system (CNS) is a sanctuary site and is protected by various barriers. These regulate brain homeostasis and the transport of endogenous and exogenous …
Alzheimer's disease (AD) is an incurable neurological illness and the leading cause of dementia, characterized by amyloid β (Aβ) fibril deposits. Caffeic acid (CA) has …